Beam Therapeutics (BEAM) Current Assets (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Current Assets data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Current Assets rose 1.55% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 1.55% YoY) and the FY2025 annual result came in at $1.3 billion, up 44.47% from the prior year.
• Current Assets held at $1.3 billion in Q1 2026 per BEAM's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.3 billion in Q4 2025 and bottomed at $878.1 million in Q4 2024.
• The 5-year median for Current Assets is $1.1 billion (2022), against an average of $1.1 billion.
• The widest annual swing landed in 2022, when Current Assets soared 140.87%; it then dropped 27.49% in 2024.
• Tracing BEAM's Current Assets over 5 years: stood at $1.1 billion in 2022, then advanced by 10.81% to $1.2 billion in 2023, then retreated by 27.49% to $878.1 million in 2024, then surged by 44.47% to $1.3 billion in 2025, then slipped by 0.14% to $1.3 billion in 2026.
• Per Business Quant, the three latest BEAM Current Assets figures stand at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.1 billion (Q3 2025).

Peer Comparison